CHMP scolds AB Sci­ence (again) for ma­sitinib short­com­ings, trig­ger­ing a new rout on stock price

AB Sci­ence has just stum­bled in­to an­oth­er set­back with its all-pur­pose an­ti-in­flam­ma­to­ry drug ma­sitinib.

The Paris-based biotech run by founder Alain Moussy says …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER